ArticleEuropean journal of clinical investigation2022
Post COVID-19 syndrome with impairment of flow-mediated epicardial vasodilation and flow reserve.
Article in European journal of clinical investigation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.
- Increased Insulin Resistance and Hyperglycaemia in Long COVID: A Systematic Review and Meta-Analysis.Expert reviews in molecular medicine · 2026Pooled it
- Prevalence of impaired flow-mediated epicardial vasodilation among different types of coronary flow regulation.The international journal of cardiovascular imaging · 2026Article
- Classical and endogen type of coronary microvascular dysfunction and potential association with cardiovascular events in a cardiometabolic disease population.The international journal of cardiovascular imaging · 2026Article
- Long-term cardiovascular impact of COVID-19 among hospitalised and non-hospitalised populations: a narrative synthesis review.Frontiers in cardiovascular medicine · 2026Review
- Long-Term Coronary Microvascular and Cardiac Dysfunction After Severe COVID-19 Hospitalization.JAMA network open · 2025Article
- Functional or structural impairment of flow-mediated epicardial vasodilation may precede coronary microvascular dysfunction.International journal of cardiology. Heart & vasculature · 2025Article
- MRI of cardiac involvement in COVID-19.The British journal of radiology · 2024Review
- COVID-19 in the Initiation and Progression of Atherosclerosis: Pathophysiology During and Beyond the Acute Phase.JACC. Advances · 2024Review
- Inflammation and Myocardial Blood Flow in Cardiac Sarcoidosis.Current cardiology reports · 2024Review
- PET/CT Assessment of Flow-Mediated Epicardial Vasodilation in Obesity and Severe Obesity.JACC. Advances · 2024Article
- Purinergic signaling: decoding its role in COVID-19 pathogenesis and promising treatment strategies.Inflammopharmacology · 2023Review
- PET-determined prevalence of coronary microvascular dysfunction and different types in a cardio-metabolic risk population.International journal of cardiology. Heart & vasculature · 2023Article
- Stress native T1 and native T2 mapping compared to myocardial perfusion reserve in long-term follow-up of severe Covid-19.Scientific reports · 2023Article
- An obscure myocardial blood flow may illuminate post-acute sequelae of COVID-19 cardiovascular syndrome.European journal of clinical investigation · 2022Article
Corrections and comments
- Commented on by
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
aimsThe aim of this study is to evaluate whether post-acute sequelae of COVID-19 cardiovascular syndrome (PASC-CVS) is associated with alterations in coronary circulatory function. MATERIALS AND
methodsIn individuals with PASC-CVS but without known cardiovascular risk factors (n = 23) and in healthy controls (CON, n = 23), myocardial blood flow (MBF) was assessed with
resultsResting MBF was significantly higher in PASC-CVS than in CON (1.29 ± 0.27 vs. 1.08 ± 0.20 ml/g/min, p ≤ .024), while hyperemic MBFs did not differ significantly among groups (2.46 ± 0.53 and 2.40 ± 0.34 ml/g/min, p = .621). The MFR was significantly less in PASC-CVS than in CON (1.97 ± 0.54 vs. 2.27 ± 0.43, p ≤ .031). In addition, there was a Δ longitudinal MBF gradient in PASC-CVS, not observed in CON (-0.17 ± 0.18 vs. 0.04 ± 0.11 ml/g/min, p < .0001).
conclusionsPost-acute sequelae of COVID-19 cardiovascular syndrome may be associated with an impairment of flow-mediated epicardial vasodilation, while reductions in coronary vasodilator capacity appear predominantly related to increases in resting flow in women deserving further investigations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.